30 results about "Combined antibiotics" patented technology

The invention discloses a method for carrying out separation and purification on algae species of euglenophyta by adopting a flat-panel solid culture medium, and relates to the technical field of purification of algae species of microalgae. The method comprises the following steps: firstly, centrifuging algae solutions of euglenophyta which is polluted by bacteria and is not subjected to separation and purification, cleaning euglenophyta slurry and removing the culture medium and physiological metabolism substances; then, coating a resistant flat panel added with composite antibiotics with thediluted algae solutions; then further drawing a line and carrying out separation and purification by adopting the resistant flat panel, then performing batch micro-culture by adopting an aseptic 96-hole cell culture plate, transferring into a triangle bottle and carrying out subsequent enlarged culture. By utilizing the method disclosed by the invention, the algae species of euglenophyta are separated, and the method has the advantages of easiness for operation, high efficiency, low cost and the like; the algae species with higher purity can be obtained in a short time, growth periods are shortened, and the probability of success of large-scale growth is improved, so that the aims of increasing the yield and reducing the cost are fulfilled.

The invention relates to the technical field of microbes and particularly discloses a method for increasing remodeling efficiency of microflora of a host intestinal tract. The method specifically comprises the steps of pretreating the host intestinal tract by using combined antibiotics, and carrying out intestinal tract caprophyl transplantation on a host. The method disclosed by the invention can be applied to a wide variety of fields such as microbial technologies, zoological medicine and nutriology. According to the method, through pretreating the host intestinal tract by using the combined antibiotics, the transplantation efficiency of caprophyl transplanting can be remarkably increased, the microflora of intestinal tracts of individuals can be efficiently changed, and the aims of disease control can be achieved if necessary.

The invention provides application of an antibiotic substitute drug melatonin in preventing the infection of meningitis escherichia coli pathogens on child patients. Meningitis-type escherichia coli is separated and identified from muscovy duck cerebrospinal fluid, a meningitis model of 3-week-old ICR mice is constructed for the first time by utilizing the strain, and the successful construction of the mouse meningitis model is evaluated from the aspects of neurological symptom scoring, mortality difference statistics, the damage degree of a blood-brain barrier, expression of meningitis-related inflammatory factors and the like respectively. With antibiotics as references, the mice are treated with the melatonin and the four combined antibiotics respectively, one week later, the disease onset conditions of the meningitis mice are detected, results show that through the melatonin and the combined use of the antibiotics, the neurological symptoms of the meningitis mice can both be reduced, the survival rate of the meningitis mice is increased, integrity keeping of the blood-brain barrier is promoted by the melatonin, the invasion of inflammatory cells into the central nervous systemis reduced, the disease onset of the meningitis in the mice is prevented through the function of the brain-gut axis, and a new antibiotic substitute and treatment strategy are provided for preventingneonatal meningitis diseases.

The combined antibiotic medicine for inhibiting beta-lactamase is prepared by combining Cefminox as one kind of the third generation of cephalosporin and beta-lactamase inhibitor in certain weight ratio. The Cefminox is in the form of its alkali metal salt or its free acid plus co-solvent; and the beta-lactamase inhibitor is Sulbactam, Clavulanic acid, tazobactam or their derivative, such as Sulperazon, tazobactam sodium, potassium Clavulanate, etc. The beta-lactamase inhibitor and Cefminox of the present invention have obvious synergistic antibiotic effect and this makes it possible to solve the increasing resistance of pathogenetic bacteria to Cefminox clinically.

The invention relates to the field of renewable energy sources of biotechnology, in particular to a method for producing citric acid by degrading coarse feed with a naturally symbiotic mixed culture.The mixed culture YakQH5 is composed of anaerobic fungi (Neocallimastix frontalis) and methane bacteria (Methanobrevibacter gottschalkii), and is preserved in China General Microbiological Culture Collection Center on March 9th, 2020, and has the preservation number of CGMCC No.19299; the mixed culture YakQH5 can degrade 15 coarse feeds respectively and produce a large amount of citric acid, especially when alfalfa is used as a substrate, the yield of citric acid reaches up to 46.0 mM, composite antibiotics are added in the fermentation process, the mixed culture can be prevented from being polluted by bacteria in the fermentation process, and the anaerobic fermentation efficiency is further improved; and the mixed culture YakQH5 provided by the invention has an important industrial application value.

The invention relates to application of cell-penetrating peptide bound gyrA gene PNA (CPP-PNA-gyrA) combined antibiotics in preparation of a medicine for inhibiting riemerella anatipestifer. After theCPP-PNA-gyrA and antibiotics co-act on the riemerella anatipestifer, the MIC (Minimal Inhibitory Concentration) on the riemerella anatipestifer is halved, so that that the CPP-PNA-gyrA is capable ofenhancing the antibacterial effects of the antibiotics. Therefore, the CPP-PNA-gyrA can be compounded with the antibiotics to prepare the medicine for resisting the riemerella anatipestifer.

The invention belongs to the technical field of medical biology, and particularly relates to application of amlodipine and cephalosporin medicines to preparation of medicine-resistant combined antibiotics. After computational biology indicates that amlodipine has an inhibitory effect on beta-lactam hydrolase, medicine testing is performed by using MRSA and acinetobacter bauamnnii as models, and through combination with cephalosporin antibiotics, a relatively good bacteriostatic effect on the MRSA is achieved; novel application is provided for the amlodipine, and a novel medicinal composition is provided for positive medicine-resistant bacteria; other more effective combinations containing the amlodipine can be further developed; the conventional cephalosporin and amlodipine combinations are mature in technology, few in side effects and low in cost; and the amlodipine and cephalosporin medicines can be applied to preparation of the medicine-resistant combined antibiotics, preparation ofbeta-lactam medicine-resistant bacterium inhibiting combined antibiotics and preparation of medicines for treating respiratory infection, wound infection and infection caused by all positive bacteria.

The invention relates to the field of renewable energy sources of biotechnology, in particular to a method for producing endoglucanase by fermenting a coarse feed substrate with a naturally symbiotic mixed culture YakQH5, the mixed culture YakQH5 is composed of anaerobic fungi (Neocallimastixfrontalis) and methane bacteria (Methanobrevibacter), different roughages can be degraded and endoglucanase with high enzyme activity can be produced. The activity of endoglucanase generated by degrading the wheat husks can reach 1170mU so that a remarkable effect is obtained; composite antibiotics are added in the fermentation process, so that the mixed culture YakQH5 can be prevented from being polluted by bacteria in the fermentation process, and the anaerobic fermentation efficiency is further improved. The mixed culture adopted in the invention can be preserved in vitro for survival and passage, popularization is convenient and production is facilitated.

The invention belongs to the technical field of animal feed additives and particularly relates to disease-preventing and growth-promoting premix feed for fattening pigs and a preparation method. The premix feed comprises components in parts by weight as follows: 6-10 parts of hawthorn fruits, 6-10 parts of medicinal fermented mass, 3-5 parts of cassia twigs, 4-6 parts of dried tangerine peels, 2-5 parts of common aucklandia roots, 6-10 parts of largehead atractylodes rhizomes, 5-7 parts of rhubarb, 3-5 parts of gentian roots, 4-6 parts of combined spicebush roots and 45-50 parts of wheat bran. The premix feed adopts natural organic plants as the raw materials, changes the conventional basis for taking chemical composition as the raw material for the fattening pigs and breaks through the weakness that chemically combined antibiotics can only alleviate symptoms for diseases and cannot prevent the diseases and consolidate the body resistance. The Chinese herbal medicines have both trophism and drug property, so that when the premix feed prepared from the Chinese herbal medicines as the raw materials is blended to feed animals, the functions of nursing for diseased animals, epidemic prevention for disease-free animals and medicinal tonifying of the spleen, animal bodies can absorb more nutrients from the feed, the nutrients can be turned into nutrient essence and multi-amino acids, and rapid growth of the animals is promoted.

The present invention provides for therapies characterized in part by co-administration or combination of antibiotic agents with medicinal compositions comprising as the pro-antibiotic active ingredient either a compound represented by a formula [I] or a pharmaceutically acceptable composite thereof; [wherein X represents oxygen, sulfur, NH, or N-alkyl; R₁ and R₂ represent hydrogen, tetrazole, or alkyltetrazole, respectively (with the restriction that if R₁ is not hydrogen, R₂ must be, and vice versa); R₃ represents e.g., benzyl, phenyl optionally substituted, biphenyl, napthyl, N-phenylcarboxamido, etc., R₄ represents e.g. carboxylic acid, or its alkyl esters, or a bioisoteric equivalent thereof, etc.; R₅ represents e.g. hydrogen, carboxylic acid, etc.] in particular, medicine which is useful as therapeutic and/or protective drugs for infectious and/or inflammatory diseases. Other relevant compounds are also provided.

The invention relates to a combined antibiotic application method for haematococcus pluvialis pure culture. A haematococcus pluvialis culture medium MCM culture medium used in an experiment is as follows: a formula of a solution A comprises 500mg/L of potassium nitrate, 20mg/L of dipotassium phosphate and 100mg/L of magnesium sulfate heptahydrate; a formula of a solution B comprises 80 mg/L of calcium chloride hexahydrate; a formula of a solution C comprises 372 [mu]g/L of disodium ethylene diamine tetraacetate and 417 [mu]g/L of ferric sulfate heptahydrate; a formula of a solution D comprises 7.189 [mu]g/L of zinc sulfate, 1.237 [mu]g/L of phosphoric acid, 0.476 [mu]g/L of cobalt chloride dehydrate, 6.242 [mu]g/L of copper sulfate pentahydrate, 8.451 [mu]g/L of manganese sulfate monohydrate and 0.726 [mu]g/L of sodium molybdate dehydrate; formula solvents are tap water, and after high-pressure sterilization, the solution A, the solution B, the solution C and the solution D dissolve in the solvents in sequence; and four antibiotics, namely streptomycin, kanamycin, gentamicin and ampicillin are combined for use, the pH value is adjusted to 6.99-7.03 and the concentration of the antibiotics are 600mu g/ml, culturing is performed on a shaker in a light box for 3 days, and purifying and inspecting are performed by combining with a solid culture medium to obtain the pure haematococcus pluvialis.

The invention relates to the technical field of dental pulp stem cells, in particular to a protective solution containing combined antibiotics for dental pulp stem cell sampling, which is characterized by comprising compound sulfafurazole, vancomycin, metronidazole, rifampicin, streptomycin, gentamicin, levofloxacin, amphotericin and diflucan. The content of the antibiotics is respectively as follows: 1 g/ML of compound sulfafurazole, 2 g/ML of vancomycin, 1 g/ML of metronidazole, 0.5 mu g/ml of rifampicin, 0.1 g/ML of streptomycin, 0.1 g/ML of gentamicin, 0.1 g/ML of levofloxacin, 0.1 g/ML of amphotericinand 100 g/ML of diflucan. Compared with the prior art, the protective solution has the advantages that the protective solution is a multi-combination effective antibiotic combination product, is suitable for collection, transportation and maintenance of tooth specimens. The protective solution is a combined antibiotic product of dental multi-connected antibiotic which can cover a plurality of microorganisms.

The invention discloses a method for enhancing antibacterial sensitivity of pseudomonas aeruginosa to antibiotics by NO. NO is provided by an exogenous NO donor, is provided by an endogenous NO donor or is accumulated by means of endogenous NO metabolism regulation, so that the antibacterial sensitivity of pseudomonas aeruginosa to one or more combined antibiotics in aminoglycoside or beta-lactam antibiotics can be enhanced, and the antibacterial sensitivity of pseudomonas aeruginosa to antibiotics can be enhanced. Meanwhile, an exogenous NO donor is provided and comprises compounds, such as SNP and GSNO, capable of directly or indirectly providing NO to an infected part, an endogenous NO donor comprises drugs, such as nitroglycerin, capable of generating NO through human metabolism, and regulation substances for endogenous NO metabolism comprise an inhibitor for inhibiting the NO metabolic process of the pseudomonas aeruginosa and a reinforcing agent for host NO synthetase. The invention finds a novel method capable of effectively enhancing the anti-sensitivity of the pseudomonas aeruginosa to the antibiotics, and related antibacterial sensitive drugs can be applied to preparation of antibacterial drugs for pseudomonas aeruginosa infection.

The invention belongs to the field of stem cell separation and culture, and particularly relates to a panda placenta mesenchymal stem cell separation and culture method. Comprising the following steps: step 1, aseptically collecting panda placentas; 2, carrying out primary isolation on the giant panda placenta mesenchymal stem cells by adopting a collagenase digestion method, and culturing the separated tissues in a culture dish; 3, performing cell morphological characteristic identification, surface marker identification and induced differentiation identification on the placenta mesenchymal stem cells cultured in the step 2; and 4, cryopreserving the cultured and subcultured placenta mesenchymal stem cells, and taking out the placenta mesenchymal stem cells for cell resuscitation when the placenta mesenchymal stem cells are used. According to the method, high-purity giant panda placenta mesenchymal stem cells are obtained by adding high-concentration combined antibiotics and cleaning for multiple times when placentas are collected, performing isolated culture by adopting a collagenase digestion method, designing marker gene specific primers of giant panda mesenchymal stem cells and the like.

The invention provides a composite antibiotic, containing penicillin sodium, chloromycetin, streptomycin sulfate and metronidazole at the weight ratio of 300-1200 to 50-200 to 150-625 to 3-12. the invention also provides a use of the composite antibiotic, specially adapted for sterilizing in the screening and culturing anaerobic fungal process. In the invention, penicillin sodium, chloromycetin, streptomycin sulfate and metronidazole with different species and concentrations are formulated, the antibacterial effect is remarkable; the composite antibiotic has simple compatibility and strong operability, is suitable for industrial production, and has higher use value especially in the feedingstuff, papermaking, fungal enzyme preparation production.